[Pubmed] Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case serie

[RSS-Bot]

Front Immunol. 2026 Mar 6;17:1788550. doi: 10.3389/fimmu.2026.1788550. eCollection 2026.

ABSTRACT

The coexistence of myasthenia gravis (MG) with other IgG-mediated autoimmune diseases represents a clinically heterogeneous condition, driven by pathogenic autoantibodies. Efgartigimod, a neonatal Fc receptor antagonist, has the ability to clear all IgG subclasses. Here, we report four cases of MG concomitant with IgG-mediated autoimmune diseases, specifically idiopathic inflammatory myopathies (IIM), Isaacs syndrome, autoimmune encephalitis (AE), and IgG4-related disease (IgG4-RD). All of them demonstrated a favorable therapeutic response to efgartigimod, with marked improvement in QMG and MG-ADL scores, along with disease-specific clinical or laboratory manifestations of the overlapping autoimmune conditions. These cases provide preliminary evidence supporting efgartigimod as a promising treatment option for patients with MG complicated by IgG-mediated autoimmune diseases.

PMID:41869344 | PMC:PMC13002818 | DOI:10.3389/fimmu.2026.1788550


Source: https://pubmed.ncbi.nlm.nih.gov/4186934 ... t6+133c1fe